聚焦2025CMEF丨飞依诺联合创始人田园：应对“关税战”，技术突破是关键

Core Viewpoint - Technological innovation is expected to be the key for the Chinese medical device industry to maintain competitiveness amid increasing global trade tensions [1] Group 1: Company Overview - Feiyin Technology Co., Ltd. was established in 2010 and is one of the few domestic companies in China's medical ultrasound industry that independently develops high-end ultrasound products [2] - In 2021, Feiyin ranked third among domestic manufacturers in terms of total sales of its ultrasound product series [2] - The company had a revenue of 446 million yuan and a net profit of 36.44 million yuan in 2021, with sales from trolley and portable ultrasound accounting for 92.43% of its main business revenue [2] Group 2: Market Position and Growth - Feiyin's overseas revenue has consistently exceeded domestic revenue, with a growth rate of over 50% in overseas business in the first quarter of this year [1][2] - The company has expanded its market presence to over 130 countries, reducing reliance on any single regional market [1] Group 3: Product Innovation - The latest flagship ultrasound product, ULTIMUS 9E Super, features advanced technologies such as URM super-resolution imaging and VFlash low-intensity ultrasound therapy [4] - The URM technology can achieve a resolution of 20 micrometers, allowing for detailed observation of microvascular conditions, which is clinically valuable [4][5] Group 4: AI Integration - Feiyin has developed comprehensive AI tools to assist doctors, covering various organs and even extending to pets [6] - The AI technology aims to enhance diagnostic efficiency by capturing suspicious lesions in real-time and providing a broader range of parameters for analysis [6][7] - The company emphasizes that AI is intended to support rather than replace doctors, acting as a "second brain" to enhance medical decision-making [6] Group 5: Market Strategy - In response to the increasing competition from centralized procurement in the medical device market, Feiyin believes the market will stratify into high-end hospitals demanding innovative products and grassroots medical institutions focusing on basic healthcare [8] - The company opposes the "low-price for market share" strategy, advocating for "value innovation" as the core competitive advantage through unique technological offerings [8]